A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II/III Clinical Trial on the Efficacy and Safety of Pirfenidone Capsules in the Treatment of Radiation-induced Lung Injury With or Without Immune-related Pneumonia
Latest Information Update: 28 Apr 2026
At a glance
- Drugs Pirfenidone (Primary)
- Indications Lung injury; Pneumonitis; Radiation injuries
- Focus Therapeutic Use
- Sponsors Beijing Continent Pharmaceutical
Most Recent Events
- 22 Apr 2026 Planned End Date changed from 30 Oct 2026 to 30 Dec 2026.
- 22 Apr 2026 Planned primary completion date changed from 30 Oct 2026 to 30 Dec 2026.
- 22 Apr 2026 Status changed from planning to recruiting.